/Moderna%20Inc%20vaccine-by%20carmengabriela%20via%20iStock.jpg)
Cambridge, Massachusetts-based Moderna, Inc. (MRNA), a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases. The company is valued at $15.9 billion by market cap. The pharmaceutical and biotechnology company is expected to announce its fiscal fourth-quarter earnings for 2025 in the near term.
Ahead of the event, analysts expect MRNA to report a loss of $2.79 per share on a diluted basis, down 11.6% from $2.50 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s bottom-line estimates in its last four quarterly reports.